CDKN2A and neoplasm: Cancer progression is understood to require the inactivation of cell‐cycle inhibitors (e.g. p53 and p16INK4a) resulting in senescence escape, cell‐cycle re‐entry and tumour cell proliferation [13, 44 Figure 2B.